Idera Pharmaceuticals, Inc. Announces Positive Phase 1 Data of IMO-2125 in Null Responder HCV Patients at EASL 2010

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL). The oral presentation, entitled “A Phase 1, Multi-Center, Randomized, Placebo-controlled, Dose-escalation Study of IMO-2125, a TLR9 Agonist, in Hepatitis C Non-responders”, was made by John McHutchison, M.D., Associate Director, Duke Clinical Research Institute and Director, Gastroenterology and Hepatology Research, Duke University Medical Center, Principal Investigator for the trial. The presentation provided additional detail from the trial regarding the interim data that was announced in December 2009.